Economic issues in lung cancer: A review

Journal of Clinical Oncology

Volumn 16, Issue 12, 1998, Pages 3900-3912

  Goodwin, Pamela J ^a   Shepherd, Frances A ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; ETOPOSIDE; NAVELBINE; VINCRISTINE; VINDESINE; ZIDOVUDINE;

CONFIDENTIALITY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; ECONOMIC ASPECT; HEALTH CARE COST; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; PRIORITY JOURNAL; REVIEW; SMOKING CESSATION;

EID: 0032407104     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.12.3900     Document Type: Review

References (66)

1. Parker SL, Toug T, Beiden S, et al: Cancer statistics 1997. Cancer J Clin 47:7-26, 1997
2. National Cancer Institute of Canada: Canadian Cancer Statistics 1997. Toronto, Canada, National Cancer Institute of Canada, 1997
3. Fraumeni JF, Blot WJ: Lung and pleura, in Schottenfeld D, Fraumeni JF (eds): Cancer Epidemiology and Prevention. Philadelphia, PA, Saunders, 1982, pp 564-582
4. Saracci R, Riboli E: Passive smoking and lung cancer: Current evidence and ongoing studies at the International Agency for Research on Cancer. Mutat Res 222:117-127, 1989
5. Desch CE, Hillner BE, Smith TJ: Economic considerations in the care of lung cancer patients. Curr Opin Oncol 8:126-132, 1996
6. Evans WK, Will BP, Berthelot J-M, et al: Estimating the cost of lung cancer diagnosis and treatment in Canada: The POHEM model. Can J Oncol 5:408-419, 1995
7. Phillips A, de Savigny D, Law MM: As Canadians butt out, the developing world lights up. Can Med Assoc J 153:1111-1114, 1995
8. Feins RH: Surgery for early-stage non-small-cell lung cancer. Semin Oncol 24:419-422, 1997
9. Rice DP, Hodgson TA, Sinsheimer P, et al: The economic costs of the health effects of smoking, 1984. Milbank Q 64:489-547, 1986
10. Drummond MF, Stoddart GL, Torrance GW: Methods for the economic evaluation of health care programmes. Oxford, England, Oxford Medical Publications, 1987
11. Bonsel GJ, Rutten FFH, Uyl-de Groot CA: Economic evaluation alongside cancer trials: Methodological and practical aspects. Eur J Cancer 29A:S10-S14, 1993 (suppl 7)
12. Laupacis A, Feenay D, Detsky AS, et al: How attractive does a new technology have to be to warrant adoption with utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 146:473-481, 1992
13. Burns D, Benowitz N, Connelly GN, et al: What should be the elements of any settlement with the tobacco industry? Tobacco Contr Int J 6:1-4, 1997
14. Annas GJ: Tobacco litigation as cancer prevention: Dealing with the devil. New Engl J Med 336:304-308, 1997
15. Kessler DA: The tobacco settlement. New Engl J Med 337:1082-1083, 1997
16. Moore MC, Mikhail CJ: A new attack on smoking using an old-time remedy. Public Health Rep 111:192-203, 1996
17. Glantz SA, Barnes DE, Bero L, et al: Looking through a keyhole at the tobacco industry: The Brown and Williamson documents. JAMA 274:219-224, 1995
18. Slade J, Bero LA, Hanauer P, et al: Nicotine and addiction: The Brown and Williamson documents. JAMA 274:225-233, 1995
19. Hanauer P, Slade J, Barnes DE, et al: Lawyer control of internal scientific research to avoid product liability lawsuits: The Brown and Williamson documents. JAMA 274:234-240, 1995
20. Bero L, Barnes DE, Hanauer P, et al: Lawyer control of the tobacco industry's external research programs: The Brown and Williamson documents. JAMA 274:241-247, 1995
21. Barnes DE, Hanauer P, Slade J, et al: Environmental tobacco smoke: The Brown and Williamson documents. JAMA 274:248-253, 1995
22. Graham T: The Brown and Williamson documents. The company's response. JAMA 274:254-255, 1995
23. Todd JS, Rennie D, McAfee RE, et al: The Brown and Williamson documents: Where do we go from here? JAMA 274:256-259, 1995
24. Freedman A, Hwang S, Lipin S, et al: Breaking away: Liggett group offers first-ever settlement of cigarette lawsuits. Wall St J March 13:A1, 1966
25. Glantz SA, Fox BJ, Lightwood JM: Tobacco litigation. Issues for public health and public policy. JAMA 277:751-753, 1997
26. Pringle P: Cornered. Big Tobacco at the Bar of Justice. New York, NY, Henry Hott, 1998
27. Luce BR, Schweitzer SO: Smoking and alcohol abuse: A comparison of their economic consequences. New Engl J Med 298:569-571, 1978
28. Office of Technology Assessment: Smoking-related deaths and financial costs. OTA Staff Memorandum. Health Program, US Congress, Washington, DC, 1985
29. Oster G, Colditz GA, Kelly NL: The economic costs of smoking and benefits of quitting for individual smokers. Prev Med 13:377-389, 1984
30. Leu RE, Schaub T: Does smoking increase medical care expenditure? Soc Sci Med 17:1907-1914, 1983
31. Barendregt JJ, Bonneux L, Von des Maas PJ: The health care costs of smoking. New Engl J Med 337:1052-1057, 1997
32. Manning WG, Keeler EB, Newhouse JP, et al: The taxes of sin. Do smokers and drinkers pay their way? JAMA 261:1604-1609, 1989
33. Lippiatt BC: Measuring medical cost and life expectancy impacts of changes in cigarette sales. Prev Med 19:515-532, 1990
34. Seeker-Walker RH, Worden JK, Holland RR, et al: A mass media programme to prevent smoking among adolescents: Costs and cost-effectiveness. Tobacco Contr 6:207-212, 1997
35. Phillips CJ, Prowle MJ: Economics of a reduction in smoking: Case study from the Heartbeat Wales. J Epidemiol Comm Health 47:215-223, 1993
36. Mackenzie TD, Bartecchi CE, Schrier RW: The human cost of tobacco use. New Engl J Med 330:975-980, 1994
37. Peterson DE, Zeger SL, Remington PL, et al: The effect of state cigarette tax increases on cigarette sales, 1955 to 1988. Am J Public Health 82:94-96, 1992
38. Borren P, Sutton M: Are increases in cigarette taxation regressive? Health Econ 1:245-253, 1992
39. Evans WK, Will BP, Berthelot J-M, et al: The economics of lung cancer management in Canada. Lung Cancer 14:19-29, 1996
40. Rosenthal MA, Webster PJ, Gebski VJ, et al: The cost of treating small-cell lung cancer. Med J Aust 156:605-610, 1992
41. Covert JA, Kopita JM, Matchar D, et al: Cost-effectiveness of collecting routine cytologic specimens during fiberoptic bronchoscopy for endoscopically visible lung tumor. Chest 109:451-456, 1996
42. Black WC, Armstrong P, Daniel TM: Cost effectiveness of chest CT in T1N0M0 lung cancer. Radiology 167:373-378, 1988
43. Eddy RJ: Cost-effectiveness of CT scanning compared with mediastinoscopy in the preoperative staging of lung cancer. J Can Assoc Radiologists 140:189-193, 1989
44. The Canadian Lung Oncology Group: Investigation for mediastinal disease in patients with apparently operable lung cancer. Ann Thorac Surg 60:1382-1389, 1995
45. Gambhir SS, Hoh CK, Phelps ME, et al: Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. J Nucl Med 37:1428-1436, 1996
46. Colice GL, Birkmeyer JD, Black WC, et al: Cost-effectiveness of head CT in patients with lung cancer without clinical evidence of metastases. Chest 108:1264-1271, 1995
47. Richardson GE, Venzon DJ, Phelps R, et al: Application of an algorithm for staging small-cell lung cancer can save one third of the initial evaluation costs. Arch Intern Med 153:329-337, 1993
48. Morrison R, Deeley TJ, Cleland W: The treatment of carcinoma of the bronchus: A clinical trial to compare surgery with supra voltage radiotherapy. Lancet i:683-684, 1963
49. Martini N, Bains MS, Burt ME, et al: Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 109:120-129, 1995
50. Sibley GS: Radiotherapy for patients with medically inoperable stage I non-small-cell lung carcinoma. Cancer 82:433-438, 1998
51. Mountain CF: Revisions in the international system for staging lung cancer. Chest 111:1710-1717, 1997
52. Evans WK, Will BP, Berthelot J-M, et al: Cost of combined modality interventions for stage III non-small-cell lung cancer. J Clin Oncol 15:3038-3048, 1997
53. Ramanathan RK, Belani CP: Chemotherapy for advanced non-small-cell lung cancer: Past, present and future. Semin Oncol 24:440-454, 1997
54. Sandier AB: Current management of small-cell lung cancer. Semin Oncol 24:463-476, 1997
55. Jaakkimainen L, Goodwin PJ, Pater J, et al: Counting the costs of cancer chemotherapy in a National Cancer Institute of Canada randomized trial in non-small-cell lung cancer. J Clin Oncol 8:1301-1309, 1990
56. Kennedy W, Reinharz D, Tessier G, et al: Cost utility of chemotherapy and best supportive care in non-small-cell lung cancer. Pharmacoeconomics 8:316-323, 1995
57. Hillner BE, Smith TJ: Cost-effective analysis of three regimens using vinorelbine (Navelbine) for non-small-cell lung cancer. Semin Oncol 23:25-30, 1996
58. Smith TJ, Hillner BE, Neighbors DM, et al: Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer. J Clin Oncol 13:2166-2173, 1995
59. Earle CC, Evans WK: A comparison of the costs of paclitaxel and best supportive care in stage IV non-small-cell lung cancer. Prev Cont Cancer 14:282-288, 1997
60. Evans WK, LeChevalier T: The cost-effectiveness of Navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small-cell lung cancer. Eur J Cancer 32 A:2249-2255, 1996
61. Vergnenègre A, Perol M, Phan E, et al: Cost analysis of hospital treatment - Two chemotherapeutic regimens for nonsurgical non-small-cell lung cancer. Lung Cancer 14:31-44, 1996
62. Palmer AJ, Brandt A: The cost-effectiveness of four cisplatin-containing chemotherapy regimens in the treatment of stages IIIB and IV non-small-cell lung cancer: An Italian perspective. Monaldi Arch Chest Dis 51:279-288, 1996
63. Williamson SK, Crowley JJ, Livingston RB, et al: Phase II trial and cost analysis of fazarabine in advanced non-small-cell carcinoma of the lung: A Southwest Oncology Group Study. Invest New Drugs 13:67-71, 1995
64. Evans WK: An estimate of the cost-effectiveness of gemcitabine in stage IV non-small-cell lung cancer. Semin Oncol 23:82-89, 1996
65. Goodwin PJ, Feld R, Evans WK, et al: Cost-effectiveness of cancer chemotherapy: An economic evaluation of a randomized trial in small-cell lung cancer. J Clin Oncol 6:1537-1547, 1988
66. Nichols CR, Fox EP, Roth BJ, et al: Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor. J Clin Oncol 12:1245-1250, 1994